N/A N=25 Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer
Glottic Carcinoma
Primary: Number of Patients With Local Failure Following SABR Treatment of Early Glottic Larynx Cancers — 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 2 N=20 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Neoplasms, Oral · Mouth Neoplasms
Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…
N/A N=278 Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
Phase 2 N=54 Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Laryngeal Cancer
Primary: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment — 27; 12 Participants
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Phase 1 N=11 Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 3; 0 Participants
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
N/A N=42 Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
Phase 2 N=52 Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
Head and Neck Cancer
Primary: Major Pathologic Response (MPR) Rate (Primary (Overall) Analysis) — 7; 10 participants
Phase 2 N=21 Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
Head and Neck Cancer
Primary: Number of Participants With Complete and Partial Response Using RECIST Criteria — 17; 2 Participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=60 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
Oropharyngeal Cancer
Primary: Percentage of Participants With Local Control — 97.9 percentage of patients
Phase 2 N=68 Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Phase 2 N=21 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Phase 2 N=48 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Phase 2 N=79 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma
Primary: Major Pathologic Response — 22 Participants
Phase 2 N=7 Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
Head and Neck Cancer · Squamous Cell Cancer
Primary: Participant Response Rate — 7 Participants
Phase 2 N=60 Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Squamous Cell Carcinoma of Oropharynx
Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 2 N=64 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate — 37.5; 5.9; 0; 16.7 percentage of patients
Phase 1 N=6 Intratumoral Cisplatin for Resectable NSCLC
Non-Small Cell Lung Cancer
Primary: Rate of Dose Limiting Toxicity — 0 participants
Phase 2 N=34 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Phase 2 N=15 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Phase 2 N=128 Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Lung Neoplasms · Squamous Cell Lung Cancer · Adenocarcinoma of the Lung
Primary: 3-year Disease-Free Survival — 96.1; 84.0 Percentage of patients at 3 years
Phase 2 N=195 P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants